S
Shelley E. Crary
High Impact
Professor, Pediatric Hematology-Oncology
faculty
20 h-index
100 pubs
1,970 cited
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Shelley E. Crary is a Professor of Pediatrics in the Division of Pediatric Hematology-Oncology at the University of Arkansas for Medical Sciences (UAMS), serving as the Medical Director of the Arkansas Center for Bleeding Disorders and Director of Hematology at Arkansas Children’s Hospital. She is also Co-Director of the UAMS Clinical and Translational Science Pilot Program and involved in structured research training programs for junior faculty and fellows, including the UAMS Master’s in Clinical and Translational Sciences Scholarship Program. Dr. Crary's research interests include gene therapy for hemophilia B, anticoagulant therapy for venous thromboembolism in pediatric patients, and treatment practices for kaposiform hemangioendothelioma and vascular malformations.
Her work has been published in journals such as Blood, Journal of Thrombosis and Haemostasis, and The Lancet. With an h-index of 20 and over 1,900 citations, her scholarship metrics indicate significant contributions to her field. Dr. Crary collaborates with researchers at UAMS, including Joana M. Mack and Divyaswathi Citla Sridhar. She maintains an active lab website detailing her research activities. Her medical and research training includes degrees from Washington University in St. Louis and Tulane University School of Medicine, followed by residency at Vanderbilt University and fellowship at UT Southwestern Medical Center, where she also earned a Master of Science in Clinical Science.
Metrics
- h-index: 20
- Publications: 100
- Citations: 1,970
Selected Publications
-
ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (2026)
-
HTRS2025.P1.27 Prevalence Vitamin D deficiency and risk factors for poor bone health in persons with Hemophilia A and B in Arkansas – A retrospective single institution study (2025)
-
Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study (2025)
-
Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease (2025)
-
End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children (2025)
-
Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies (2025)
-
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment (2025)
-
Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease (2025)
-
Pediatric hematology: selected topics (2025)
-
Hemostasis and thrombosis risks and management in vascular anomalies (2024)
-
Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children (2024)
-
Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes (2024)
-
What is in a name: defining pediatric refractory ITP (2024)
-
A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders (2024)
-
Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study (2023)
Grants & Funding
Collaboration Network
Top Collaborators
Joana M. Mack
University of Arkansas for Medical Sciences
14 shared publications
In database
- Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
- How we approach coagulopathy with vascular anomalies
- Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?
- Anticoagulation and vascular anomalies
- Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes
Showing 5 of 14 shared publications
Divyaswathi Citla Sridhar
University of Arkansas for Medical Sciences
9 shared publications
In database
- Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
- HTRS2023.P3.5 Screening for abnormal uterine bleeding in adolescents presenting to primary care clinics
- Poor School Performance As an Indicator of Severity of Sickle Cell Disease
- Mental health in persons with von Willebrand disease in the United States – a large national database study
- A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders
Showing 5 of 9 shared publications
Taizo A. Nakano
Children's Hospital Colorado (US)
7 shared publications
- Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
- What is in a name: defining pediatric refractory ITP
- Treatment practices and response in Kaposiform hemangioendothelioma: a multi-center cohort study
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
Showing 5 of 7 shared publications
Kerry Hege
Riley Hospital for Children (US)
7 shared publications
- What is in a name: defining pediatric refractory ITP
- The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- The Fuvid Study: Functional Characterization of Children with Pulmonary Embolism in a Prospective Multicenter Cohort Study
Showing 5 of 7 shared publications
Alexandra J. Borst
University of North Carolina at Chapel Hill (US)
5 shared publications
- Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
- Barriers to Genetic Testing in Vascular Malformations
- Treatment practices and response in Kaposiform hemangioendothelioma: a multi-center cohort study
- Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations
- Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies
Amanda B. Grimes
Children's Cancer Center (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Shipra Kaicker
Cornell University (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Rukhmi Bhat
Lurie Children's Hospital (US)
5 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- The Fuvid Study: Functional Characterization of Children with Pulmonary Embolism in a Prospective Multicenter Cohort Study
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Michele P. Lambert
Children's Hospital of Philadelphia (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Manpreet Kochhar
Hasbro Children's Hospital (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Melissa J. Rose
Nationwide Children's Hospital (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Sanjay Shah
Center for Cancer and Blood Disorders (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Michael Briones
Children's Healthcare of Atlanta (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Jeffrey D. Lebensburger
University of Alabama at Birmingham (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Alexis A. Thompson
Children's Hospital of Philadelphia (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Similar Researchers
Based on overlapping research topics
Nysia I. George
National Center for Toxicological Research
Child and Adolescent Health
Health Sciences Research and Education
Cancer Treatment and Pharmacology
A Andres
University of Arkansas for Medical Sciences
Child and Adolescent Health
Health Sciences Research and Education
Cancer Treatment and Pharmacology
E Børsheim
University of Arkansas for Medical Sciences
Child and Adolescent Health
Health Sciences Research and Education
Cancer Treatment and Pharmacology
T Swindle
University of Arkansas for Medical Sciences
Child and Adolescent Health
Health Sciences Research and Education
Cancer Treatment and Pharmacology
Sung W. Rhee
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Vascular Malformations and Hemangiomas
Health Sciences Research and Education
D Citla-Sridhar
University of Arkansas for Medical Sciences
Platelet Disorders and Treatments
Child and Adolescent Health
Health Sciences Research and Education